Food, Drugs, Healthcare, Life Sciences

The Hon’ble Delhi High Court has granted a permanent injunction in favour of the American pharmaceutical and medical devices giant Johnson & Johnson (“J&J”), restraining a New Delhi-based entity from infringing its trademarks ‘Surgicel’, ‘Ligaclip’ and ‘Ethicon’, and from manufacturing, distributing, or selling counterfeit surgical devices. Recognising the grave public health risks posed by counterfeit medical products, the Court also awarded damages amounting to approximately ₹3.34 crore against the defendants.

India's life sciences, pharmaceutical, and consumer healthcare sectors are entering a more enforcement-driven regulatory phase. Recent interventions by the Central Government, the Central Drugs Standard Control...

Synergistic combinations in patent law present unique challenges for inventors in chemical, pharmaceutical, and life sciences fields. While combining known components is common practice, only those combinations producing effects greater than the sum of their parts can constitute patentable inventions. This article explores the legal requirements, evidentiary standards, and practical strategies for successfully claiming synergistic effects under Australian patent law.

India's pharmaceutical patent system navigates the delicate balance between protecting innovation and ensuring affordable access to life-saving medicines for millions living in poverty. Through mechanisms like compulsory licensing and restrictions on patent evergreening, the country attempts to honor its TRIPS obligations while maintaining its role as the "Pharmacy of the World." How effectively do these legal safeguards reconcile the competing interests of global pharmaceutical giants and public health nee

A case on appeal in NSW focused on whether a sentence handed down for drug supply charges was excessive.

India's life sciences, pharmaceutical, and consumer healthcare sectors are entering a more enforcement-driven regulatory phase. Recent interventions by the Central Government, the Central Drugs Standard Control...

Ministerial Direction 105 allows the government to issue instructions to Home Affairs on how skilled visas should be prioritised, typically taking into account regional needs, sponsorship status and critical sectors.

The Hon’ble Delhi High Court has granted a permanent injunction in favour of the American pharmaceutical and medical devices giant Johnson & Johnson (“J&J”), restraining a New Delhi-based entity from infringing its trademarks ‘Surgicel’, ‘Ligaclip’ and ‘Ethicon’, and from manufacturing, distributing, or selling counterfeit surgical devices. Recognising the grave public health risks posed by counterfeit medical products, the Court also awarded damages amounting to approximately ₹3.34 crore against the defendants.

India's pharmaceutical patent system navigates the delicate balance between protecting innovation and ensuring affordable access to life-saving medicines for millions living in poverty. Through mechanisms like compulsory licensing and restrictions on patent evergreening, the country attempts to honor its TRIPS obligations while maintaining its role as the "Pharmacy of the World." How effectively do these legal safeguards reconcile the competing interests of global pharmaceutical giants and public health nee